{"id":7677,"date":"2020-03-11T06:44:19","date_gmt":"2020-03-11T06:44:19","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/"},"modified":"2020-03-11T06:44:19","modified_gmt":"2020-03-11T06:44:19","slug":"nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/","title":{"rendered":"Nicox : Paiement de 15 millions d&rsquo;euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[16,34],"tags":[],"class_list":["post-7677","post","type-post","status-publish","format-standard","hentry","category-actualites-et-media","category-communiques-de-presse"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Paiement de 15 millions d&#039;euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Paiement de 15 millions d&#039;euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence - Nicox\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-11T06:44:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Paiement de 15 millions d&rsquo;euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence\",\"datePublished\":\"2020-03-11T06:44:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\\\/\"},\"wordCount\":40,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s et M\u00e9dia\",\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\\\/\",\"name\":\"Nicox : Paiement de 15 millions d'euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-03-11T06:44:19+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Paiement de 15 millions d'euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Paiement de 15 millions d'euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence - Nicox","og_url":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/","og_site_name":"Nicox","article_published_time":"2020-03-11T06:44:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/"},"author":{"name":"","@id":""},"headline":"Nicox : Paiement de 15 millions d&rsquo;euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence","datePublished":"2020-03-11T06:44:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/"},"wordCount":40,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s et M\u00e9dia","Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/","url":"https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/","name":"Nicox : Paiement de 15 millions d'euros et prise en charge de la moiti\u00e9 des co\u00fbts de la deuxi\u00e8me \u00e9tude clinique de phase 3 sur NCX 470 par Ocumension Therapeutics dans le cadre d\u2019un amendement de leur accord de licence - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2020-03-11T06:44:19+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-paiement-de-15-millions-deuros-et-prise-en-charge-de-la-moitie-des-couts-de-la-deuxieme-etude-clinique-de-phase-3-sur-ncx-470-par-ocumension-therapeutics-dans-le-cadre-dun-amendemen\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=7677"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/7677\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=7677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=7677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=7677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}